Literature DB >> 2834604

[Thrombocyte function in essential thrombocythemia and reactive thrombocytosis].

B Baumann1, I Hillmar, R Hehlmann.   

Abstract

Blood of 16 patients with essential thrombocythemia (ET), 9 patients with reactive thrombocytosis (RT) and 13 healthy persons was used for platelet aggregation studies. When the aggregation was induced with adenosine diphosphate (0.01 microM), collagen (0.1 micrograms/ml) or platelet activating factor (PAF 0.5 microM) the plasma of the patients with ET showed significantly decreased aggregation (35%-44% of the value for the control groups). Independent of inhibitors of platelet aggregation, thrombin (0.05 U/ml) caused similar aggregation in healthy controls and patients with ET; patients with RT showed an increase aggregation. Adrenalin-induced aggregation discriminated best between patients with ET and controls. Adrenalin in concentrations ranging from 0.01 micrograms/ml to 100 micrograms/ml caused comparable dose-related amounts of aggregation in healthy controls and patients with RT. Over the whole concentration range, patients with ET showed significantly decreased aggregation (28%-34% of the value for the control groups). This difference proved to be independent of the influence of inhibitors of platelet aggregation. Though concentrations of alpha1-acid glycoprotein never reached inhibitory levels in the plasma of patients with ET (n = 12) they were significantly higher compared with those in normal plasma (n = 12). Fibrinogen concentrations in plasma of ET-patients (n = 12) were in the normal range. Cellular adenosine 3'-5'-cyclic monophosphate concentrations in ET (n = 10) are comparable with normal values (n = 5). The significance of the results for diagnosis and better pathophysiological understanding of ET is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834604     DOI: 10.1007/BF01728197

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  32 in total

1.  THE AGGREGATION OF BLOOD PLATELETS.

Authors:  G V BORN; M J CROSS
Journal:  J Physiol       Date:  1963-08       Impact factor: 5.182

2.  Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.

Authors:  S Murphy; H Iland; D Rosenthal; J Laszlo
Journal:  Semin Hematol       Date:  1986-07       Impact factor: 3.851

3.  [Methods for the quantitative determination of plasma proteins by immunoprecipitation].

Authors:  W Becker; W Rapp; H G Schwick; K Störiko
Journal:  Z Klin Chem Klin Biochem       Date:  1968-05

4.  On the fine structure and aggregation requirements of gel filtered platelets (GFP).

Authors:  O Tangen; E L McKinnon; H J Berman
Journal:  Scand J Haematol       Date:  1973

5.  Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.

Authors:  K Yamamoto; E Sekiguchi; O Takatani
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

Review 6.  Normal mechanisms of platelet function.

Authors:  J Vermylen; P N Badenhorst; H Deckmyn; J Arnout
Journal:  Clin Haematol       Date:  1983-02

7.  [Platelet aggregation and prostaglandin turnover in man during defined linoleic acid supply with formula diets (author's transl)].

Authors:  O Adam; M Dill-Wiessner; G Wolfram; N Zöllner
Journal:  Res Exp Med (Berl)       Date:  1980

8.  Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function.

Authors:  B J Boughton; W E Corbett; A D Ginsburg
Journal:  J Clin Pathol       Date:  1977-03       Impact factor: 3.411

9.  Platelet hyperaggregability and thrombosis in patients with thrombocythemia.

Authors:  K K Wu
Journal:  Ann Intern Med       Date:  1978-01       Impact factor: 25.391

10.  Platelet function in patients with high platelet counts.

Authors:  A D Ginsburg
Journal:  Ann Intern Med       Date:  1975-04       Impact factor: 25.391

View more
  3 in total

1.  A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia.

Authors:  G Middelhoff; I Boll
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

2.  [Clinical characterization of essential thrombocythemia in comparison with other myeloproliferative diseases and reactive thrombocytoses].

Authors:  M Jahn; B Zönnchen; W Köpcke; R Hehlmann
Journal:  Klin Wochenschr       Date:  1988-03-01

3.  [Megakaryocytic myelosis--clinical aspects, morphology and platelet function].

Authors:  A Hochhaus; D Höche; K Mindner; G Ostermann; M Meyer
Journal:  Klin Wochenschr       Date:  1989-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.